<DOC>
	<DOCNO>NCT02465983</DOCNO>
	<brief_summary>This study pancreatic cancer patient receive combination therapy CART-meso cell CART19 cell administer 3 day one dose cyclophosphamide . CART-meso cell patient ' T cell modify laboratory express receptor specific mesothelin protein . CART19 cell patient ' T cell modify laboratory express receptor specific protein call CD19 . The CD19 protein express white blood B cell . CART19 cell expect attack B cell impede antibody response CART-meso cell . The investigator hypothesize combination therapy may prolong duration CART-meso cell body . Additionally , one dose cyclophosphamide may enhance engraftment persistence CART cell .</brief_summary>
	<brief_title>Pilot Study Autologous T-cells Patients With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>Immunotherapy novel promise approach treatment solid tumor ; immunotherapy chimeric antigen receptor ( CAR ) T cell ( CART cell ) particular potential advantage target therapy invoke rapid tumor response , advantage long-lived response hallmark engagement adaptive immune system memory T cell . This single arm , open-label , phase I study determine safety feasibility combination CART-meso cell ( autologous T cell lentivirally transduce express anti-mesothelin scFv fuse TCRζ 4-1BB costimulatory domain ) CART19 cell ( autologous T cell lentivirally transduce express humanize anti-CD19 scFv fuse TCRζ 4-1BB costimulatory domain ) patient pancreatic cancer follow lymphodepletion cyclophosphamide .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Signed informed consent Unresectable metastatic pancreatic cancer Persistent cancer least one prior standard care chemotherapy advance stage disease 18 year age old ECOG performance status 0 1 Life expectancy great 3 month Satisfactory organ bone marrow function Meets blood coagulation parameter Male Female subject reproductive potential agree use approve contraceptive method Participation therapeutic investigational study within 4 week prior screen visit Anticipated need systemic chemotherapy within 2 week apheresis infusion Active invasive cancer pancreatic cancer HIV , HCV , HBV infection Active autoimmune disease require immunosuppressive therapy within 4 week prior screen visit , exception thyroid replacement Ongoing active infection Planned concurrent treatment systemic high dose corticosteroid Patients require supplemental oxygen therapy Prior therapy gene modify cell Previous experimental therapy SS1 moiety , murine chimeric antibody History allergy murine proteins History allergy hypersensitivity study product excipients ( human serum albumin , DMSO , Dextran 40 ) Clinically significant pericardial effusion , CHF , cardiovascular condition would preclude assessment mesothelin induce pericarditis may worsen result toxicity expect study Pregnant breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>CAR / CART</keyword>
	<keyword>T cell</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Gene therapy</keyword>
	<keyword>Redirected T cell</keyword>
	<keyword>Autologous T cell</keyword>
</DOC>